Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>De novo</i> Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel <i>In vivo</i> Breast Tumor Model

10 Nov 2009

Abstract excerpt

Notch pathway signaling plays a fundamental role in normal biological processes and is frequently deregulated in many cancers. Although several hypotheses regarding cancer subpopulations most likely to respond to therapies targeting the Notch pathway have been proposed, clinical utility of these predictive markers has not been shown. To understand the molecular basis of gamma-secretase inhibitor (GSI) sensitivity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Developmental Biology and Gene Regulation
Share to TGF-β signaling in diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19903844
DOI: 10.1158/0008-5472.can-09-1544

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>De novo</i> Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel <i>In vivo</i> Breast Tumor ModelPMID 19903844Read ↗

S1-5: Modulation of Cancer and Stem Cell Biomarkers by the Notch Inhibitor MK-0752 Added to Endocrine Therapy for Early Stage ER+ Breast Cancer.Semantic proximity Read ↗

Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.Semantic proximity Read ↗

Notch Signaling Pathway as a Therapeutic Target in Breast CancerSemantic proximity Read ↗

Modulation of Oncogenic NOTCH Signaling in Highly Aggressive Neoplasia by Targeting the G-Secretase Complex. A Systematic ReviewSemantic proximity Read ↗

Modulation of Oncogenic NOTCH Signaling in Highly Aggressive Malignancies by Targeting the γ-Secretase Complex: A Systematic ReviewSemantic proximity Read ↗

The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancerSemantic proximity Read ↗

More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.Semantic proximity Read ↗

ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitorSemantic proximity Read ↗

A High Notch Pathway Activation Predicts Response to γ Secretase Inhibitors in Proneural Subtype of Glioma Tumor-Initiating CellsSemantic proximity Read ↗

Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines.Semantic proximity Read ↗

NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitroSemantic proximity Read ↗

Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survivalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.